Alex Allepuz

677 total citations
15 papers, 134 citations indexed

About

Alex Allepuz is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Alex Allepuz has authored 15 papers receiving a total of 134 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 11 papers in Genetics and 5 papers in Rheumatology. Recurrent topics in Alex Allepuz's work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Eosinophilic Disorders and Syndromes (5 papers). Alex Allepuz is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Eosinophilic Disorders and Syndromes (5 papers). Alex Allepuz collaborates with scholars based in Switzerland, United States and Japan. Alex Allepuz's co-authors include Paola Aimone, Florence Hourcade‐Potelleret, Alexey Maschan, Keon Hee Yoo, Carmelo Rizzari, Carla Boquimpani, Francisco Bautista, Delphine Réa, Carlo Dufour and Stéphane Ducassou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Bone and Joint Surgery.

In The Last Decade

Alex Allepuz

15 papers receiving 133 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alex Allepuz Switzerland 6 100 72 36 29 19 15 134
Steegmann Jl Spain 6 133 1.3× 62 0.9× 30 0.8× 41 1.4× 7 0.4× 9 142
Laure Morisset France 4 70 0.7× 39 0.5× 22 0.6× 16 0.6× 5 0.3× 5 119
Katsuhiro Shono Japan 7 71 0.7× 31 0.4× 5 0.1× 35 1.2× 12 0.6× 20 134
John Feigert United States 6 187 1.9× 166 2.3× 8 0.2× 9 0.3× 13 0.7× 7 239
Sa-Hee Park South Korea 6 127 1.3× 100 1.4× 63 1.8× 13 0.4× 2 0.1× 9 155
Kristina Myhr‐Eriksson Sweden 7 160 1.6× 95 1.3× 45 1.3× 29 1.0× 2 0.1× 7 180
Sonia Maria Orlando Italy 5 40 0.4× 59 0.8× 24 0.7× 4 0.1× 10 0.5× 12 99
Francisco Bracho United States 6 33 0.3× 19 0.3× 8 0.2× 18 0.6× 14 0.7× 12 96
Thomas Noesslinger Austria 4 31 0.3× 24 0.3× 19 0.5× 7 0.2× 13 0.7× 15 79
Stefana Impera Italy 6 85 0.8× 54 0.8× 8 0.2× 35 1.2× 3 0.2× 14 140

Countries citing papers authored by Alex Allepuz

Since Specialization
Citations

This map shows the geographic impact of Alex Allepuz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Allepuz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Allepuz more than expected).

Fields of papers citing papers by Alex Allepuz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Allepuz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Allepuz. The network helps show where Alex Allepuz may publish in the future.

Co-authorship network of co-authors of Alex Allepuz

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Allepuz. A scholar is included among the top collaborators of Alex Allepuz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Allepuz. Alex Allepuz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Kuter, David J., Mathias Rummel, Philip Choi, et al.. (2024). A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3. Blood. 144(Supplement 1). 710–710. 1 indexed citations
2.
Réa, Delphine, Carla Boquimpani, Michael J. Mauro, et al.. (2023). Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 37(5). 1060–1067. 8 indexed citations
3.
4.
5.
Hughes, Timothy P., Delphine Réa, Carla Boquimpani, et al.. (2022). Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study. Blood. 140(Supplement 1). 6757–6759. 3 indexed citations
6.
Yuda, Junichiro, Noriko Doki, Hiroshi Matsuoka, et al.. (2022). Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. Cancer Medicine. 12(3). 2990–2998. 4 indexed citations
7.
Hijiya, Nobuko, Alexey Maschan, Carmelo Rizzari, et al.. (2021). A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Advances. 5(14). 2925–2934. 19 indexed citations
8.
Hoch, Matthias, Masahiko Sato, Michelle Quinlan, et al.. (2021). Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment. The Journal of Clinical Pharmacology. 61(11). 1454–1465. 19 indexed citations
9.
10.
Hijiya, Nobuko, Alexey Maschan, Carmelo Rizzari, et al.. (2019). Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia. Blood. 134(23). 2036–2045. 37 indexed citations
11.
Mauro, Michael J., Andreas Hochhaus, Carla Boquimpani, et al.. (2019). A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology. 37(15_suppl). TPS7070–TPS7070. 3 indexed citations
12.
Mauro, Michael J., Andreas Hochhaus, Carla Boquimpani, et al.. (2019). A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs. Clinical Lymphoma Myeloma & Leukemia. 19. S286–S287. 2 indexed citations
13.
14.
15.
Allepuz, Alex, Leif I Havelin, Thomas Barber, et al.. (2014). Effect of Femoral Head Size on Metal-on-HXLPE Hip Arthroplasty Outcome in a Combined Analysis of Six National and Regional Registries. Journal of Bone and Joint Surgery. 96(Supplement_1). 12–18. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steegmann Jl Breakdown of academic impact, for papers by Laure Morisset Breakdown of academic impact, for papers by Katsuhiro Shono Breakdown of academic impact, for papers by John Feigert Breakdown of academic impact, for papers by Sa-Hee Park Breakdown of academic impact, for papers by Kristina Myhr‐Eriksson Breakdown of academic impact, for papers by Sonia Maria Orlando Breakdown of academic impact, for papers by Francisco Bracho Breakdown of academic impact, for papers by Thomas Noesslinger Breakdown of academic impact, for papers by Stefana Impera
Rankless by CCL
2026